Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 2Withdrawn 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Wound Infection 1Urinary Tract Infections 1Stomatitis 1Sepsis 1Prostatic Neoplasms 1Pleural Effusion, Malignant 1Head and Neck Neoplasms 1Fever 1Esophageal Neoplasms 1Breast Neoplasms 1

Interventions

Carboplatin 7Paclitaxel 6Talc 5Docetaxel 5Bevacizumab 4Taxes 3Gemcitabine 3Cisplatin 3Trastuzumab 2High-Energy Shock Waves 2Erlotinib Hydrochloride 2Doxycycline 2Cetuximab 2Bortezomib 2viscum album peptide 1tipifarnib 1saracatinib 1romidepsin 1endostar protein 1Zoledronic Acid 1Vinorelbine 1Valacyclovir 1Tyrosine Kinase Inhibitors 1Thoracoscopy 1Thoracoscopes 1Thoracic Surgery, Video-Assisted 1Thoracentesis 1Surveys and Questionnaires 1Sorafenib 1Povidone-Iodine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Pleural Effusion, Malignant × Povidone-Iodine × Clear all
NCT02674243 2020-01-23

Efficacy of Iodopovidone Versus Talc in Palliative Malignant Pleural Effusion

Chiang Mai University

Phase 3 Completed
60 enrolled
Thoracic

Pleural Effusion, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡